Article Menu
- Academic Editor
- Subscribe SciFeed
- Recommended Articles
- Related Info Links
-
More by Authors Links
- on DOAJ
- Ciérvide, R.
- Montero, Á.
- García-Rico, E.
- García-Aranda, M.
- Herrero, M.
- Skaarup, J.
- Benassi, L.
- Barrera, M. José
- Vega, E.
- Rojas, B.
- Bratos, R.
- Luna, A.
- Parras, M.
- López, M.
- Delgado, A.
- Quevedo, P.
- Castilla, S.
- Feyjoo, M.
- Higueras, A.
- Prieto, M.
- Suarez-Gauthier, A.
- Garcia-Cañamaque, L.
- Escolán, N.
- Álvarez, B.
- Chen, X.
- Alonso, R.
- López, M.
- Hernando, O.
- Valero, J.
- Sánchez, E.
- Ciruelos, E.
- Rubio, C.
- on Google Scholar
- Ciérvide, R.
- Montero, Á.
- García-Rico, E.
- García-Aranda, M.
- Herrero, M.
- Skaarup, J.
- Benassi, L.
- Barrera, M. José
- Vega, E.
- Rojas, B.
- Bratos, R.
- Luna, A.
- Parras, M.
- López, M.
- Delgado, A.
- Quevedo, P.
- Castilla, S.
- Feyjoo, M.
- Higueras, A.
- Prieto, M.
- Suarez-Gauthier, A.
- Garcia-Cañamaque, L.
- Escolán, N.
- Álvarez, B.
- Chen, X.
- Alonso, R.
- López, M.
- Hernando, O.
- Valero, J.
- Sánchez, E.
- Ciruelos, E.
- Rubio, C.
- on PubMed
- Ciérvide, R.
- Montero, Á.
- García-Rico, E.
- García-Aranda, M.
- Herrero, M.
- Skaarup, J.
- Benassi, L.
- Barrera, M. José
- Vega, E.
- Rojas, B.
- Bratos, R.
- Luna, A.
- Parras, M.
- López, M.
- Delgado, A.
- Quevedo, P.
- Castilla, S.
- Feyjoo, M.
- Higueras, A.
- Prieto, M.
- Suarez-Gauthier, A.
- Garcia-Cañamaque, L.
- Escolán, N.
- Álvarez, B.
- Chen, X.
- Alonso, R.
- López, M.
- Hernando, O.
- Valero, J.
- Sánchez, E.
- Ciruelos, E.
- Rubio, C.
Need Help?
Order Article Reprints
Journal: Cancers, 2022
Volume: 14
Number: 4531
4531
Article:
Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination
Authors:
by
Raquel Ciérvide, Ángel Montero, Eduardo García-Rico, Mariola García-Aranda, Mercedes Herrero, Jessica Skaarup, Leticia Benassi, Maria José Barrera, Estela Vega, Beatriz Rojas, Raquel Bratos, Ana Luna, Manuela Parras, María López, Ana Delgado, Paloma Quevedo, Silvia Castilla, Margarita Feyjoo, Ana Higueras, Mario Prieto, Ana Suarez-Gauthier, Lina Garcia-Cañamaque, Nieves Escolán, Beatriz Álvarez, Xin Chen, Rosa Alonso, Mercedes López, Ovidio Hernando, Jeannette Valero, Emilio Sánchez, Eva Ciruelos and Carmen Rubioadd
Show full author list
remove
Hide full author list
Link:
https://www.mdpi.com/2072-6694/14/18/4531
MDPI offers high quality article reprints with convenient shipping to destinations worldwide. Each reprint features a 270 gsm bright white cover
and 105 gsm premium white paper, bound with two stitches for durability and printed in full color. The cover design is customized to your article
and designed to be complimentary to the journal.
Cite
Ciérvide, R.; Montero, Á.; García-Rico, E.; García-Aranda, M.; Herrero, M.; Skaarup, J.; Benassi, L.; Barrera, M.J.; Vega, E.; Rojas, B.; et al. Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination. Cancers 2022, 14, 4531. https://doi.org/10.3390/cancers14184531
Ciérvide R, Montero Á, García-Rico E, García-Aranda M, Herrero M, Skaarup J, Benassi L, Barrera MJ, Vega E, Rojas B, et al. Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination. Cancers. 2022; 14(18):4531. https://doi.org/10.3390/cancers14184531
Chicago/Turabian StyleCiérvide, Raquel, Ángel Montero, Eduardo García-Rico, Mariola García-Aranda, Mercedes Herrero, Jessica Skaarup, Leticia Benassi, Maria José Barrera, Estela Vega, Beatriz Rojas, and et al. 2022. "Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination" Cancers 14, no. 18: 4531. https://doi.org/10.3390/cancers14184531
APA StyleCiérvide, R., Montero, Á., García-Rico, E., García-Aranda, M., Herrero, M., Skaarup, J., Benassi, L., Barrera, M. J., Vega, E., Rojas, B., Bratos, R., Luna, A., Parras, M., López, M., Delgado, A., Quevedo, P., Castilla, S., Feyjoo, M., Higueras, A., ... Rubio, C. (2022). Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination. Cancers, 14(18), 4531. https://doi.org/10.3390/cancers14184531
